PHARMACEUTICAL FORMS WITH IMPROVED PHARMACOKINETIC PROPERTIES

Formulation (I) that disintegrates quickly in the mouth, comprises vardenafil, where at least 80% of the vardenafil dose dissolves at 25[deg]C in 10 ml of physiological saline and the release rate of (I) in 900 ml of physiological saline is at least 70% within the first 5 minutes in the USP (titaniu...

Full description

Saved in:
Bibliographic Details
Main Authors SERNO PETER, PAULI KERSTIN, HAYAUCHI YUTAKA, HEINIG ROLAND
Format Patent
LanguageEnglish
Slovenian
Published 31.07.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Formulation (I) that disintegrates quickly in the mouth, comprises vardenafil, where at least 80% of the vardenafil dose dissolves at 25[deg]C in 10 ml of physiological saline and the release rate of (I) in 900 ml of physiological saline is at least 70% within the first 5 minutes in the USP (titanium dioxide) sheet agitator device at 50 revolutions per minute at 37[deg]C. ACTIVITY : None given. MECHANISM OF ACTION : Cyclic guanosine monophosphate phosphodiesterase inhibitor. No biological data given.
Bibliography:Application Number: SI20060031352T